Cannabis Report
Home > Boards > US Listed > Medical - Drugs >

TrovaGene, Inc. (TROV)

Add TROV Price Alert      Hide Sticky   Hide Intro
Moderator: $Pistol Pete$
Search This Board: 
Last Post: 8/29/2018 8:43:26 AM - Followers: 60 - Board type: Free - Posts Today: 0

Trovagene logoTrovagene, Inc. 
11055 Flintkote Ave., Suite B
San Diego, CA 92121
Tel: USA [+1] 858 217 4838
Fax: USA [+1] 858 217 4768 
TrovaGene, Inc. is a publicly traded company molecular diagnostics company, with headquarters in San Diego, California. We are dedicated to the development and commercialization of unique, proprietary, molecular in-vitro diagnostics technologies. 
The company's founding scientists were the first to report that cell free fragments of DNA from normal cell death that circulate in the blood can cross the kidney barrier and be detected in urine. 
These cell-free nucleic fragments that pass through the kidney ("transrenal" or Tr-DNA/RNA) can be used as genetic markers of disease. The company believes that this transrenal technology will open significant new markets in the molecular diagnostics field and lead to improvements in the area of personalized medicine.

TroveGene, Inc. news

Attention: Gabriele Cerrone, Director of Trovagene
Gabriele Cerrone, Founder and Chairman of FermaVir Pharmaceuticals.
FermaVir Pharmaceuticals was bought out by Inhibitex (INHX) in 2007 and Gabriele Cerrone was appointed a Director of the acquiring company.
Bristol-Myers Squibb offered $2.5 Billion to acquire Inhibitex.

Bristol-Myers Squibb to Acquire Inhibitex

InhibitexReleased: 01/07/12 09:13 PM EST
Bristol-Myers Squibb Company (NYSE:BMY) and Inhibitex, Inc. (Nasdaq:INHX) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger. The transaction, with an aggregate purchase price of approximately $2.5 billion, has been approved by the boards of directors of both companies. The board of directors of Inhibitex has agreed to recommend that Inhibitex's shareholders tender their shares in the tender offer. In addition, shareholders with beneficial ownership of approximately 17% of Inhibitex's common stock have entered into agreements with Bristol-Myers Squibb to support the transaction and to tender their shares in the tender offer.

Gabriele Cerrone holds an 11.4% interest in Trovagene.


Trovagene Closes Acquisition of CLIA Laboratory Assets
SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, today announced that it has closed its acquisition of MultiGEN Diagnostics, Inc.'s clinical laboratory assets.  Trovagene previously announced the execution of the Asset Acquisition Agreement on January 6, 2012.

Antonius Schuh, Ph.D. Joins TrovaGene, Inc. As Chief Executive Officer

SAN DIEGO--(BUSINESS WIRE)-- TrovaGene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, has announced that Antonius Schuh, Ph.D. has been named Chief Executive Officer. Dr. Schuh previously served as Chairman and Chief Executive Officer of Sorrento Therapeutics, Inc. (Pink Sheets: SRNE.PK), a biotechnology company he co-founded based on a proprietary platform to generate very large fully human antibody libraries. Sorrento Therapeutics merged in 2009 with a public company supported by Phillip Frost and the Frost Group.
Dr. Schuh also served as the founding CEO of AviaraDx, Inc., a leading molecular diagnostic innovator in oncology. In 2008, Dr. Schuh led the sale of AviaraDx to bioMerieux, which continues to operate AviaraDx under the name bioTheranostics. Before AviaraDx, Dr. Schuh served as CEO of Arcturus Bioscience, Inc., where he led the sale of Arcturus' life science business to Molecular Devices, Inc. From 2000 to 2005, Dr. Schuh served as the President and Chief Executive Officer of Sequenom, Inc. (Nasdaq: SQNM - News). He had joined Sequenom in 1996 as Managing Dierctor of its European operations, and led during his tenure, amongst others, the commercial launch of the MassARRA® system and numerous business development and corporate acquisition transactions. Dr. Schuh holds a degree in pharmaceutics and earned his Ph.D. in medicinal chemistry from the University of Bonn, Germany.
"We are pleased and fortunate that Dr. Schuh joins us to lead the transition of TrovaGene from a research stage organization to a commercial enterprise," states Dr. Thomas Adams, TrovaGene's Chairman. "The company has made significant efforts to establish the utility of trans-renal nucleic acids in urine as a diagnostic sample in clinical fields as diverse as detection of minimal residual disease in oncology, infectious disease, transplant medicine and prenatal monitoring. Dr. Schuh has a proven track record of building companies and creating value for shareholders. I look forward to working with him."
"I have observed TrovaGene closely over the past years, as I have been intrigued by the attractive opportunities the Company's proprietary trans-renal technologies offer, and I am confident that we can introduce novel diagnostic modalities with significant clinical utility based on this platform," states Dr. Schuh.

TROV executives
TROV board

Targeted $40 Billion market space:
TROV market space

Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TROV News: Current Report Filing (8-k) 09/18/2018 10:38:29 AM
TROV News: Trovagene Announces Participation at The MicroCap Conference on October 1st and 2nd at the Essex House in New York City 09/18/2018 08:30:00 AM
TROV News: Current Report Filing (8-k) 09/13/2018 04:32:45 PM
TROV News: Current Report Filing (8-k) 09/05/2018 11:35:25 AM
TROV News: Trovagene Announces Predictive Clinical Biomarker Approach to Identify Acute Myeloid Leukemia (AML) Patients Most Likely to R... 09/05/2018 08:00:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#1169   News MegaDeath 08/29/18 08:43:25 AM
#1168   Strong day! Maybe more to follow next week... Klinsmann 08/24/18 04:04:53 PM
#1167   TROV - Here we go folks. Huge monies Fares 08/24/18 02:57:59 PM
#1166   If you don't see solid ROI from current Fares 08/20/18 12:50:36 PM
#1165   Tell me why would the ceo resign after stockmule 08/16/18 02:38:15 PM
#1164   This puppy is extremely undervalued. Period. Fares 08/16/18 02:25:18 PM
#1163   No happy pills needed - looks bottomed. On Klinsmann 08/14/18 04:16:53 PM
#1162   LOL are you on happy pills? Johnny_C 08/14/18 10:55:01 AM
#1161   TROV - Reversal in progress folks. Fares 08/10/18 02:49:45 PM
#1160   yes my friend, trading goodly mick 08/02/18 09:13:52 PM
#1159   Nice close today $Pistol Pete$ 08/02/18 09:12:03 PM
#1158 mick 08/02/18 08:54:15 PM
#1157   * * $TROV Video Chart 08-02-18 * * ClayTrader 08/02/18 04:45:22 PM
#1156   TROV - Strong uptick. Delayed rally in progress. Fares 08/02/18 02:59:40 PM
#1155   Lols Agserina 08/01/18 01:22:55 PM
#1154   Added my position here today $Pistol Pete$ 08/01/18 10:27:08 AM
#1153   It is all good here Go $TROV $Pistol Pete$ 08/01/18 09:48:38 AM
#1152   Trovagene Common Sto (TROV) mick 08/01/18 09:44:48 AM
#1151   $TROV Daily and Weekly Charts http://www.stock $Pistol Pete$ 08/01/18 09:35:59 AM
#1150   Good news $Pistol Pete$ 08/01/18 09:23:40 AM
#1149   TROV News: Trovagene Receives Positive Opinion for Orphan cjstocksup 08/01/18 09:00:07 AM
#1148   Nice $Pistol Pete$ 08/01/18 08:51:04 AM
#1147   4.9 million shares. Very low. cjstocksup 08/01/18 08:40:12 AM
#1146   Great TROV news today! Nice small float. Could cjstocksup 08/01/18 08:22:03 AM
#1145   Just read a blog that mentioned TROV and DesertEagle 07/26/18 07:36:03 AM
#1144   volume of a dropping entity is failure, down Full Contact Yoga 07/23/18 07:38:24 PM
#1143   In for 95K shares @ .796 does TROV Sbailey08 07/23/18 02:03:40 PM
#1141   Massive fail how ? Friday’s volume was crazy Sbailey08 07/22/18 09:24:48 PM
#1140   * * $TROV Video Chart 07-20-18 * * ClayTrader 07/20/18 04:25:26 PM
#1139   massive fail here, shouldn't do much until sub .60 Full Contact Yoga 07/18/18 12:44:58 PM
#1138   Looks bottomed to me - starter next week Klinsmann 07/13/18 10:00:00 AM
#1137   Sound good and I will go in with $Pistol Pete$ 07/12/18 04:22:28 PM
#1136   Same here my friend. Have several on watch. Klinsmann 07/12/18 04:21:58 PM
#1135   I want to see if this is something $Pistol Pete$ 07/12/18 04:20:02 PM
#1134   Good question. As always difficult to get reliable Klinsmann 07/12/18 04:19:08 PM
#1133   What is the outstanding shares here? $Pistol Pete$ 07/12/18 04:15:55 PM
#1132   On close watch, esp. after that "downward dance"... Klinsmann 07/09/18 09:01:51 AM
#1131   No cents watching this thing anymore, it had FloatinGator 07/02/18 10:34:40 AM
#1130   Lower than average volume and price almost hit stockmule 06/29/18 05:45:25 PM
#1129   Dead cat bounce, big pump coming or something stockmule 06/29/18 09:44:36 AM
#1128   Not yet. Big day coming soon GangstaKitty 06/28/18 11:08:15 PM
#1127   stick a fork in it FloatinGator 06/28/18 03:36:18 PM
#1126   They really kicked rocks on this one. The FloatinGator 06/27/18 03:44:29 PM
#1125   I am thinking BK at some point. No stockmule 06/26/18 06:40:23 PM
#1124   .80 bottom? Attila1905 06/26/18 01:00:54 PM
#1123   Probably just going to swim around here for FloatinGator 06/26/18 10:18:39 AM
#1122   Wow I didn't see that coming, lol. Bill stockmule 06/25/18 10:51:04 AM
#1121   The ceo resign and the director buying shares. MasterChi 06/22/18 11:29:11 PM
#1120   smelling like FREEF here, down again... FloatinGator 06/22/18 02:49:13 PM
#1119   Down day on positive news FloatinGator 06/21/18 12:36:15 PM